Neovacs S.A. (ALNEV.PA)

EUR 1.11

(-11.15%)

Net Debt Summary of Neovacs S.A.

  • Neovacs S.A.'s latest annual net debt in 2023 was -237.08 Thousand EUR , down -120.49% from previous year.
  • Neovacs S.A.'s latest quarterly net debt in 2024 Q2 was 248.39 Thousand EUR , down 0.0% from previous quarter.
  • Neovacs S.A. reported annual net debt of 1.15 Million EUR in 2022, up 107.6% from previous year.
  • Neovacs S.A. reported annual net debt of -15.22 Million EUR in 2021, down -57.15% from previous year.
  • Neovacs S.A. reported quarterly net debt of -237.08 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.
  • Neovacs S.A. reported quarterly net debt of -237.08 Thousand EUR for 2023 FY, down -120.49% from previous quarter.

Annual Net Debt Chart of Neovacs S.A. (2023 - 2009)

Historical Annual Net Debt of Neovacs S.A. (2023 - 2009)

Year Net Debt Net Debt Growth
2023 -237.08 Thousand EUR -120.49%
2022 1.15 Million EUR 107.6%
2021 -15.22 Million EUR -57.15%
2020 -9.68 Million EUR -681.25%
2019 -1.23 Million EUR -4.41%
2018 -1.18 Million EUR 55.95%
2017 -2.69 Million EUR -4595.56%
2016 59.96 Thousand EUR 144.52%
2015 -134.68 Thousand EUR -107.41%
2014 1.81 Million EUR 220.42%
2013 567.44 Thousand EUR 302.41%
2012 -280.33 Thousand EUR 96.41%
2011 -7.8 Million EUR -24.3%
2010 -6.28 Million EUR -258.73%
2009 3.95 Million EUR 0.0%

Peer Net Debt Comparison of Neovacs S.A.

Name Net Debt Net Debt Difference
ABIONYX Pharma SA -714 Thousand EUR 66.795%
ABIVAX Société Anonyme -196.47 Million EUR 99.879%
Adocia SA 127 Thousand EUR 286.683%
Aelis Farma SA -16.19 Million EUR 98.536%
Biophytis S.A. 2.7 Million EUR 108.771%
Advicenne S.A. 12.17 Million EUR 101.947%
genOway Société anonyme 2.97 Million EUR 107.975%
IntegraGen SA -709.74 Thousand EUR 66.596%
Medesis Pharma S.A. 1.15 Million EUR 120.47%
NFL Biosciences SA -2.27 Million EUR 89.583%
Plant Advanced Technologies SA 4.35 Million EUR 105.442%
Quantum Genomics Société Anonyme -830.54 Thousand EUR 71.454%
Sensorion SA 1.37 Million EUR 117.202%
Theranexus Société Anonyme 2.44 Million EUR 109.7%
TME Pharma N.V. -1.07 Million EUR 78.027%
Valbiotis SA -18.13 Million EUR 98.693%
TheraVet SA 12.78 Thousand EUR 1954.415%
Valerio Therapeutics Société anonyme 2.18 Million EUR 110.876%
argenx SE -1.83 Billion EUR 99.987%
BioSenic S.A. 28.04 Million EUR 100.845%
Celyad Oncology SA -6.1 Million EUR 96.115%
DBV Technologies S.A. -114.95 Million USD 99.794%
Galapagos NV -157.2 Million EUR 99.849%
Genfit S.A. -7.61 Million EUR 96.885%
GeNeuro SA 5.91 Million EUR 104.011%
Hyloris Pharmaceuticals SA -25.11 Million EUR 99.056%
Innate Pharma S.A. -30.71 Million EUR 99.228%
Inventiva S.A. 10.48 Million EUR 102.26%
MaaT Pharma SA -10.2 Million EUR 97.677%
MedinCell S.A. 39.5 Million EUR 100.6%
Nanobiotix S.A. -24.71 Million EUR 99.041%
Onward Medical N.V. -12.89 Million EUR 98.161%
Oryzon Genomics S.A. 1.43 Million EUR 116.576%
OSE Immunotherapeutics SA 27.12 Million EUR 100.874%
Oxurion NV 10.71 Million EUR 102.214%
Pharming Group N.V. 99.4 Million EUR 100.239%
Poxel S.A. 44.55 Million EUR 100.532%
GenSight Biologics S.A. 16.29 Million EUR 101.455%
Transgene SA -14.4 Million EUR 98.355%
Financière de Tubize SA 78.62 Million EUR 100.302%
UCB SA 2.17 Billion EUR 100.011%
Valneva SE 82.73 Million EUR 100.287%
Vivoryon Therapeutics N.V. -18.52 Million EUR 98.72%